Angiotensin-converting enzyme inhibitors (ACEi) exert cardiovascular and renal actions and have expanded effects on glucose and lipid metabolism in non-classic target organs.
Do ACE inhibitors exert beneficial effects on glucose and lipid metabolism in non-classic target organs?
ACE inhibitors may have beneficial effects on glucose and lipid metabolism in non-classic target organs due to local RAAS expression.
The main function of the renin-angiotensin-aldosterone system (RAAS) is the regulation of blood pressure; therefore, researchers have focused on its study to treat cardiovascular and renal diseases. One of the most widely used treatments derived from the study of RAAS, is the use of angiotensin-converting enzyme inhibitors (ACEi). Since it was discovered, the main target of ACEi has been the cardiovascular and renal systems. However, being the RAAS expressed locally in several specialized tissues and cells such as pneumocytes, hepatocytes, spleenocytes, enterocytes, adipocytes, and neurons the effect of inhibitors has expanded, because it is expected that RAAS has a role in the specific function of those cells. Many chronic degenerative diseases compromise the correct function of those organs, and in most of them, the RAAS is overactivated. Therefore, the use of ACEi must exert a benefit on an impaired system. Accordingly, the objective of this review is to present a brief overview of the cardiovascular and renal actions of ACEi and its effects in organs that are not the classic targets of ACEi that carry on glucose and lipid metabolism.
Silva‐Velasco et al. (Mon,) conducted a review in Cardiovascular and renal diseases. Angiotensin-converting enzyme inhibitors (ACEi) was evaluated. Angiotensin-converting enzyme inhibitors (ACEi) exert cardiovascular and renal actions and have expanded effects on glucose and lipid metabolism in non-classic target organs.